Health Robotics re-acquires European rights for CytoCare from B. Braun

Health Robotics and B. Braun Melsungen AG today announced that in exchange for undisclosed consideration, Health Robotics has re-acquired from B. Braun the exclusive marketing, sales, installation, implementation, interface, manufacturing, and technical support European rights for CytoCare, a robot designed to manufacture chemotherapy and hazardous IV Admixtures, and which rights B. Braun had previously acquired from Health Robotics in 2007 and 2008. This amendment to the prior agreements includes the transition of all CytoCare customer contracts from B. Braun to direct Health Robotics' technical support starting on July 1st, 2010.

"Health Robotics' current global dominance of the IV Robotics industry is in great part due to the support we received from B. Braun since 2006. We learnt a lot from B. Braun through the last 42 months, especially in the area of flexibility supporting many different IV consumables, which has improved our robots not only for B. Braun's IV Bottles but also for Asia Pacific-based IV consumables. We will always owe a debt of gratitude to B. Braun and we hope to continue with B. Braun the joint cooperation in IV consumables, as we expand Health Robotics to directly market and support selected European countries in the next development phase for the company," stated Werner Rainer, Health Robotics' CEO.

In addition to the above mentioned undisclosed consideration, Health Robotics has agreed with B. Braun to continue to support B. Braun's market leading IV consumables such as Ecoflac Plus bottles, Easypump elastomeric devices, Excel and PAB I.V. Bags, Omnifix syringes, and TEC 1000 syringe caps, the latter being the only syringe cap supported by Health Robotics for its other, non hazardous IV robot: i.v.STATION.

"We also learnt a lot from this experience, especially as we expand B. Braun's horizons from its market-leading position in IV Therapy and Nutrition products into the complexity of Clinical IT solutions, requiring extensive Project Management skills at customers' locations," stated Dr. Torsten Doenhoff, B. Braun's Vice President Marketing & Sales Drug Admixture and Application Systems.